Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month ...

A new pancreatic cancer treatment may finally move the needle on what's proved to be an unforgiving disease. Fred Hutch ...

Monash University's Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median ...

Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...

A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...

Finerenone also reduced albuminuria at month 12 by 42% and lowered the risk of kidney failure or an eGFR decline of 40% or ...

Treeline Biosciences, a well-funded cancer company that has raised more than $1 billion since its 2021 founding, is looking ...

Shares of Tango Therapeutics gained after the company reported positive initial data from an ongoing study of a potential treatment for pancreatic cancer. The stock climbed 45% to $29.24 in premarket ...

A two-drug combination exhibited durable clinical benefit as second- or third-line treatment for pancreatic cancer, according to a topline data announcement released by one of the agent’s ...

We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Revolution Medicines (NASDAQ ...

Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...